Selskabets formål er at undersøge om et stof fra Big Pharma kan anvendes sammen med DRPTM.
| Year | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 33 t. | 174 t. | 4 t. | -2.5 mio. | - | |
CVR: 38445928
Secondary names: OV-SPV2 ApS, Oncology Venture SPV2 ApS
Companies in the same industry and area
CVR 34623562
CVR 29526346
CVR 37728403
CVR 40279865
CVR 63717916
Jeffrey Stuart Ervin joined as director
Alexander Epshinsky left as director
companydata.dk